Anthropic has officially launched Claude Science, a dedicated AI research workbench engineered to streamline scientific discovery and automate complex data workflows for researchers. Announced on June 30, 2026, the standalone platform unifies fragmented specialised tools, databases, and compute management into a single, cohesive user interface tailored for computational biology, genomics, and chemistry.
Designed to operate directly on the user’s local device rather than in a web browser, Claude Science serves as an agentic workspace that alleviates the tedious context switching that traditional workflows require. The system features a generalist coordinating agent that can spin up specialised sub-agents, handle data pipelines, and manage demanding compute workloads across high-performance clusters (HPC) or cloud networks.
A key highlight of Claude Science is its deep native integration with the scientific ecosystem, coming pre-configured with over 60 curated scientific databases including PubMed, bioRxiv, and the Protein Data Bank. The platform possesses the ability to natively render complex visual artefacts, such as 3D protein structures, chemical geometries, and genome browser tracks.
Crucially, every piece of visual data, manuscript draft, or analytical figure generated by the tool is completely reproducible. The workspace logs an auditable history tracing all outputs back to their specific source code, environmental configurations, and conversational context, enabling peer researchers to easily validate the findings.
Parallel to this launch, the company introduced its highly agentic Claude Sonnet 5 model, optimised for cost-effective execution within these research workflows. For ultra-complex reasoning tasks that require even deeper computational budgets, researchers can also leverage the newly integrated Claude Opus 4.8. The platform is currently available in beta for premium Claude subscribers on macOS and Linux, positioning Anthropic to capture a larger share of the lucrative pharmaceutical and biotech sectors as it prepares for its heavily anticipated IPO.
